World News – AU – Billionaire Ray Dalio’s son was killed in a car accident

Billionaire Ray Dalio announced that his son Devon Dalio was killed in a car accident on Thursday afternoon.

« It is with great pain that I am telling you that my 42-year-old son was killed in a car accident yesterday, » Dalio said in a tweet on Saturday.

We know that the terrible pain we feel has been and is being felt by so many others that our condolences go out to them. May God be with you and may you appreciate your blessings, especially at this time of year.

« My family and I grieve and process and would prefer to be out of touch with the outside world for the time being.

“We know that the terrible pain we feel has been and is being felt by so many others that our condolences go out to them. May God be with you and may you appreciate your blessings, especially at this time of year. ”

Devon Dalio’s car reportedly crashed into a Verizon store in Connecticut’s Riverside Commons mall.

A family spokesman told Hearst Connecticut it was « a heartbreaking tragedy and the family is in mourning ». .

Devon is survived by his wife, daughter, parents Annie and Ray, and three siblings. He was a co-founder and partner of P-Squared Private Equity and a board member of his family’s foundation. He also previously worked for his father’s hedge fund, Bridgewater Associates.

Ray Dalio, who recently spoke at the Yahoo Finance All Markets Summit, is an American billionaire, hedge fund manager, and philanthropist who founded Bridgewater Associates, the world’s largest hedge fund, in 1975.

Dalio has been the co-chief investment officer of Bridgewater Associates since 1985. It now manages around $ 138 billion.

The billionaire is also a bestselling author and publishes the New York Times bestseller No.. 1 and the bestseller from Amazon No.. 1 Principles: Life & Work.

In April 2011, Dalio and his wife joined Bill Gates and Warren Buffett’s Giving Pledge and pledged to donate more than half of their fortune to charitable causes in their lives.

Want to hear Australian influencers share their best finance tips? Join the Broke Millennials Club on Facebook and get one hot tip per day in December.

And if you want 2021 to be your best (financial) year yet, follow Yahoo Finance on Facebook, LinkedIn, Instagram and Twitter. Subscribe to the free daily newsletter with full instruction here.

COLUMBUS, Ohio, Dec.. . 18, 2020 (GLOBE NEWSWIRE) – Green Growth Brands Inc. . (CSE: GGB) (OTCQB: GGBXF) (« GGB » or the « Company ») and some of its direct and indirect wholly-owned subsidiaries (collectively the « Applicants ») today updated their bankruptcy proceedings under the Creditors Arrangement Act (Canada) (« CCAA »). As already announced, the applicants applied for and applied for. May 2020 Protection by the CCAA by the Ontario Supreme Court (the « Court »). On the 18th. December 2020 the Court of Justice issued two orders, including (a) an amendment of 17. Greenspace LLC (“All Js”) dated Dec. 19, 2020 (the “DIP Change”) to the Owned Debtor Term Sheet between the Company and All Js. May 2020 in the currently valid version; and (b) the stay of proceedings under the CCAA up to and including May 26. March 2021 extended. A copy of the orders issued and entered by the court, the DIP change, and other court materials and information relating to the applicants’ CCAA process, all of which may be updated or changed from time to time, are on the website maintained by Ernst available & Young Inc. . in his capacity as a monitor appointed by the court (“Monitor”) the applicant at www. ey. com / ca / ​​ggbi. All inquiries regarding the CCAA process should be directed to the monitor. Applicants intend to provide further updates to the CCAA process as there are significant developments. Florida License Transfer Approval The Company previously announced the expiration of the grace period under the terms of the Forbearance Agreement with Green Ops Group LLC (« Green Ops ») and the subsequent commencement of the approval process by Green Ops for the state to Florida transfers the cannabis license by Spring Oaks Greenhouses, Inc. . The transfer of the cannabis license to Green Ops was announced on Jan.. Approved by the State of Florida December 2020. Nevada License Transfer Approval The Company today announced that it has received approval from the Nevada Cannabis Compliance Board (“CCB”) to transfer the licenses of Nevada Organic Remedies LLC, Henderson Organic Remedies LLC, and Wellness Orchards of Nevada LLC Under the previously announced and approved stalking horse contract between the Company, All Js and Capital Transfer Agency, ULC in its capacity as trustee of the debtor of the aggregate face value of $ 15. 500. $ 000 (A) of 45. 500. $ 000. 00% secured convertible bonds with a term up to 17th. May 2020 and (B) 23. 717. $ 000 total face value of 5. 00% secured convertible bonds with a term until 2024. The CCB’s approval is subject to the payment of an agreed penalty by the GGB in connection with the formation and insertion of certain intermediaries by the GGB prior to formal approval by Nevada regulators. About Green Growth Brands Inc. . Green Growth Brands has licenses for cannabis operations in Nevada, Massachusetts and Florida. Its brands include CAMP, The Source, and 8Fold. Forward-Looking Information Certain information in this press release contains forward-looking statements within the meaning of applicable securities law. All statements in this press release that are not historical facts may be considered forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions. adverse events in industry; Marketing costs; Loss of markets; future legislative and regulatory developments related to medical marijuana and recreational marijuana; Inability to access sufficient capital from internal and external sources and / or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory issues; the company’s ability to execute its business strategies; Competition; Currency and interest rate fluctuations and other risks, including those under the heading “Risk Factors” in (i) the Company’s Annual Information Form dated December 26,. November 2018, which is available in the company’s issuer profile on SEDAR and (ii) the company’s brief prospectus dated November 15, 2018. August 2019. Readers are cautioned that the above list is not exhaustive. Readers are cautioned not to place undue reliance on forward-looking statements as there can be no guarantee that the plans, intentions or expectations for which they are made will materialize. Although such information is believed by management to be reasonable at the time of preparation, it could prove to be incorrect and actual results could differ materially from those expected. The forward-looking statements contained in this press release speak as of the date of this release and the company undertakes no obligation to update or revise any forward-looking information as a result of new information, future events or otherwise, except as required by securities law. Forward-looking statements in this press release are expressly qualified by this cautionary statement. U.S. Securities Act Disclaimer This announcement does not constitute an offer, invitation, or recommendation to subscribe for or buy any securities. Neither this announcement nor the information contained therein forms the basis of any contract or obligation. In particular, this announcement does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States and may not be offered or offered directly or indirectly within the United States In the United States, unless the securities have been registered under the Securities Act or there is an exception to the registration requirements of the Securities Act. For investor relations inquiries, please contact: Kent Kiffner General Counsel Green Growth Brands Inc. . kkiffner @ greengrowthbrands. com

Before watching the CNN Live special, Dr. . Sheba Roy ND FABNO discusses the potential health benefits of psilocybin and CBD in the data via ZoomTUCSON, AZ, Dec.. . 18, 2020 (GLOBE NEWSWIRE) – via NewMediaWire – Anything Technologies Media, Inc. . (OTC: EXMT) and Minerco, Inc. . (OTC: MINE) announced today that they have teamed up to offer the first ever « Shroom Zoom » viewing and Q&A regarding the potential health benefits of psilocybin and CBD. Visit us on Sunday the 20th. December, at 9:00 p.m. EST for an engaging and dynamic zoom presentation by Dr.. . Sheba Roy, a supportive cancer specialist with Associates of Integrative Medicine in Michigan. DR. Roy’s Clinic hosts masters and doctoral level counselors who treat trauma, PTSD, depression, anxiety, grief and loss with a powerful combination of therapeutic counseling, nutrition and natural therapies. We’ll be following the discussion with a zoomed-in view of the CNN Live Special « Psychedelic Healing, » which will be released at 10pm EST by Lisa Ling https: // www. cnncreativemarketing. com / project / thisislife /. This Is Life With Lisa Ling is a groundbreaking documentary series that sheds light on what was formally « taboo » and how it can change the way we think about ourselves and the world around us. The feature from 20. December will highlight the emerging science around psilocybin and CBD in the treatment of mental health problems and goals for optimal wellness. After the CNN Live Special, we will have a live Q&A session with Dr. . Roy from Zoom. Minerco, Inc. . and Anything Technologies Media are committed to providing our communities with exceptional opportunities to be at the forefront of transformative healing. Watch us and register below: https: // zoom. us / meet / register / tJYod-mvqTotGdJuRrBhoodPnOWLnYPhA0ivAbout Anything Technologies Media, Inc. . (OTC: EXMT) Anything Technologies Media is a manufacturing and marketing company engaged in the sale and marketing of CBD Health products and software applications. ATM is the parent company of the subsidiaries and focuses on partnerships and acquisitions in new technologies and in the manufacturing sector. The company and its partners each have their own professional management team with extensive backgrounds in finance, manufacturing, marketing and sales. The goal of ATM is to combine the expertise of our team members to create a cohesive force that moves the company forward in the marketplace. About Minerco, Inc. . (OTC: MINE) Minerco, Inc. . (OTC: MINE) was recently acquired by a psilocybin research and investment firm and is becoming the world’s first publicly traded company focused on the research, manufacture and distribution of psilocybin mushrooms. MINE also developed Blockchain Token SHRU to create a payment gateway for retail purchases. Please follow https: // twitter. com / minercoincInvestor Relationsminers @ minercoinc. via Sonoran Flower LLC. https: // sonoranflower. com / storeSonoran Flower is based on the belief that nature contains everything we need to heal. We are a diverse organization that grows, processes, and sells hemp products in wholesale and retail. We source and produce high quality hemp seeds, smokable hemp flowers, hemp biomass, distillates, isolates and products such as vape, lotions, ointments and hemp beverages. To purchase Sonoran Flower CBD products, call 520-303-HEMP (4367). Follow us on Twitter @ https: // twitter. com / anywastechmedFollow us on Instagram @ https: // www. instagram. com / anywascbdmeds / About Amethyst Beverage: https: // www. Amethyst drink. com / Amethyst Beverage, a Reno, NV based company, was founded in October 2016 primarily as a policy in support of a philanthropic initiative against cancer-related children and adults. A portion of all sales will go to multiple organizations at the national level. Currently, Amethyst Beverage is the only water on the market that has patented, USDA organic, vegan and kosher certifications, and it is also the only flavored water (strawberry / watermelon, orange / mango, pineapple / coconut, cran / razz, cucumber / Mint and peach) alkaline water with fulvic acid, which also contains 70 ionic minerals. Safe Harbor Statement Certain statements in this press release constitute forward-looking statements based on management’s expectations, estimates, projections and beliefs. Words such as « expects, » « anticipates, » « plans, » « believes, » « plans, » « estimates » and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Therefore, actual future results and trends could differ materially from those projected in any forward-looking statement due to a variety of factors. All forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to update or publicly release any changes to any forward-looking statement to reflect events, circumstances, or changes in expectations after the date of this press release. Anything Technologies Media, Inc. . info @ anytechnologiesmedia. com

Lianhua Qingwen Capsules, an innovative traditional Chinese patent medicine, is manufactured by China’s Yiling Pharmaceutical under the guidance of the TCM Collateral Disease Theory. It has been widely used for symptoms caused by mild and moderate COVID-19, such as fever, cough, and fatigue. It was recommended by the Diagnosis and Treatment Protocol for COVID-19 (Study Version 4-8) jointly published by the Chinese National Health Commission and the National Administration of TCM. On 23. Lianhua Qingwen was introduced to the Philippines on November 1st, and many Filipino consumers have rushed to buy this medicine.

A campaign shell firm, founded in part by Jared Kushner, spent half of President Donald Trump’s massive war chest and secretly paid Trump family members and employees, according to a bombshell report in Business InsiderFriday.

Two children from Sydney spend Christmas in hotel quarantine after arriving in Victoria.

A new study suggests that a state election was not the only reason Queensland meeting days fell below the national average.

(Bloomberg) – Moderna Inc. . The Covid-19 vaccine was approved by U. S.. . Regulators, second vaccine to receive emergency approval this month as historic mass vaccination was carried out across the country. The Food and Drug Administration’s decision on Friday to approve the use of the shot in adults means two of the six vaccine candidates identified by Operation Warp Speed ​​are now open to the public, which was accomplished in less than a year. Recordings from AstraZeneca Plc and Johnson & Johnson, who also received U.. S.. . Government support is expected to be submitted for review next year. Moderna’s shot was developed by the National Institutes of Health and manufactured by Pfizer Inc. . and BioNTech SE, which was released last week, is based on messenger RNA technology not previously used in vaccines. For Moderna, whose ticker symbol is MRNA, it is also the company’s first product to be approved for use by regulators. On Thursday, a group of outside FDA advisors voted 20-0 with one abstention for the shot, which has not been approved in any other country and has not yet been used on anyone outside of a clinical trial. Delivery of the vaccine to the U. . S.. . The government will begin immediately and a full approval application is expected next year, Moderna said in a statement. « I am proud of what the Moderna team has achieved in collaboration with our partners, » said Stéphane Bancel, CEO of the company. “We continue to focus on expanding production to protect as many people as possible from this terrible disease. Monitoring reactions Moderna’s vaccine, like Pfizer’s, is administered as a two-dose regimen. Moderna said the most common side effects after receiving the shots were injection site pain, swelling, and swollen lymph nodes. Most of the reactions were mild or moderate. The FDA is investigating five allergic reactions related to Pfizer’s vaccine in the United States. S.. . Peter Marks, director of the agency’s office that monitors the vaccines, said on a call with reporters Friday. Some allergic reactions were also reported in the U. K. . where Pfizer’s shot was approved earlier this month, including two that involved a serious reaction called anaphylaxis. An ingredient in the vaccine called polyethylene glycol, which is also found in Moderna’s shot, « could be a culprit here, » Marks said. The compound is « unusually associated » with allergic reactions, he said, although « these allergic reactions might be more common than the unusual ones we thought. « The FDA and at least a handful of other federal programs pay close attention to vaccine side effects that have not been seen in clinical trials. The agency has asked vaccine-delivery facilities to have drugs available to treat allergic reactions. The Moderna vaccine does not require any special equipment to be kept cold. Pfizer must be kept in ultra-cold freezers, however Moderna can be kept in a standard freezer like the one found in most household kitchens. This should facilitate distribution and ease of use for many pharmacies. Operation Warp Speed, the Trump administration’s drive to accelerate vaccine development, provided Moderna with more than $ 950 million to develop the vaccine. The U. S.. . has pledged to spend billions to buy 200 million doses, enough to immunize 100 million people, with an option to buy another 300 million. The option to get more doses could be particularly important for the launch of the vaccine in the US. S.. . , one of the most far-reaching mass vaccination campaigns ever carried out. United Parcel Service Inc. . As part of an agreement with McKesson, the vaccine will be delivered by Moderna, the freight giant said in a statement on Friday. Moderna’s vaccine is 94. 1% effective in preventing symptomatic cases of Covid-19 and was able to prevent the most serious infections according to the FDA’s analysis of clinical trial results. Pfizer and BioNTech’s vaccine is 95% effective. Both shots far exceed the minimum standard of 50% effectiveness set by the FDA for the elimination of potential coronavirus vaccines. « With the availability of two vaccines to prevent Covid-19, the FDA has taken another crucial step in the fight against this global pandemic that causes large numbers of hospitalizations and deaths in the US every day, » said FDA Commissioner Stephen Hahn said in a statement. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, said in a statement that he hoped that “all Americans will protect themselves through vaccination when the vaccine is available to them. So our country will begin to heal and move forward. “Scaling When it comes to bringing a new product onto the market on a massive scale, Moderna as a young company has not yet been tested. However, it can be half or more of the early U.. S.. . Vaccine inventory. This is because during the U. . S.. . bought 100 million cans from Pfizer last summer – enough for 50 million people – and initially passed on the opportunity to purchase more. On Thursday, Moncef Slaoui, Chief Scientific Advisor to Operation Warp Speed, told the U. . S.. . is close to a deal for an additional 100 million cans of Pfizer. Pfizer, maker of some of the best-selling drugs of all time, such as the cholesterol fighter Lipitor and erectile dysfunction drug Viagra, said it had to fill orders from other countries before satisfying a new U.. S.. . Demand for more shots. Health and Human Services Secretary Alex Azar said Wednesday that Jan.. 9 million doses of Moderna’s vaccine would be shipped quickly across the country once approved. He said that 2. 9 million doses of Pfizer’s vaccine have already run out and another 2 million doses of the Pfizer shot will run out next week. Moderna expects to be able to produce 20 million cans for the U.. S.. . by the end of the year and another 85 to 100 million cans in the U. . S.. . in the first quarter. In total, Moderna and its manufacturing partner Lonza Group AG plan to produce 500 to 1 billion doses of its vaccine in 2021. The European Union, Canada and Japan also have major sales contracts with the company and the U. . K. . has secured 7 million cans. Placebo IssuePfizer has already begun enabling healthcare workers who participated in the study and received the placebo to switch to the actual vaccine as they are approved under U.. S.. . Guidelines currently to get the shot. When asked if Moderna would take a similarly phased approach, Marks declined to comment, saying that the U talks would continue. S.. . Regulators and the company. Moderna announced at the FDA advisors meeting Thursday that it would like to give its vaccine to all volunteers who received the placebo, and not wait. Bloomberg previously reported that Moderna hopes to offer the vaccine to these volunteers within a week or two of emergency approval, according to a letter to some study participants. Moderna, based in Cambridge, Massachusetts, became one of the most highly valued private biotechnology companies before it first sold shares to the public in December. 2018. Although the company had worked on developing numerous vaccines from the start, its work on a potential personalized cancer vaccine received the most attention. Investors were initially skeptical of the stock as the company did not have a portfolio of approved products to generate reliable sales and had declined around 15% between its debut and the start of this year. But since the company started working on its vaccine, stocks have risen more than eight-fold. (Updates with FDA comments on allergic reactions from Jan.. Paragraph) You can find more articles like this at bloomberg. comSubscribe now to stay one step ahead with the most trusted business news source. © 2020 Bloomberg L. . P. .

The growing number of COVID-19 cases in Sydney has raised serious concerns about the famous Australian yacht race.

Ayna Garayeva, a school teacher in the capital of authoritarian and secretive Turkmenistan, began taking extra hygiene measures in her classroom when the government issued new guidelines in August.

MALVERN, Pa. , Dec. . Sep. 18, 2020 (GLOBE NEWSWIRE) – Recro (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of oral solids at the commercial and development stage of Dose Drug Products announced today that it has awarded an incentive award to its newly appointed President and Chief Executive Officer, David Enloe. The allocation consists of 217. 822 restricted stock units and an option to purchase 194. 175 common shares of Recro. The award was presented on 15. December 2020 under the NASDAQ Incentive Exemption as part of Mr.. . Enloe’s compensation and was granted as incentive material for accepting employment with Recro under NASDAQ Listing Rule 5635 (c) (4). . With regard to the restricted stock units, 19. 802 on 15. Be fully vested by December 2021; 132. 013 will be from 15. Transferred December 2021 in four equal annual installments; and 66. 007 will vest after certain performance-related milestones have been reached, which were set by the Recro Compensation Committee, subject to Mr.. Enloe’s continued service with Recro until the relevant exercise date. The options will be available from the 15th. Transferred in equal monthly installments over 48 months, subject to January 1, 2021. Enloe’s continued service with Recro until the relevant exercise date. The options have an exercise price of USD 3. 03 per share of Recro’s common stock and expires on Dec.. December 2030. About RecroRecro is a contract development and manufacturing organization (CDMO) with integrated solutions for the formulation, analytical services, regulatory support, manufacturing and packaging of solid oral drugs in the development and development phase. Recro’s clinical trial materials and logistics business, including clinical trial double-blind delivery preparation and delivery logistics, is becoming a popular service as well as specialized service functions dedicated to the development and manufacture of high-impact GMP products. The company leverages its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies and other manufacturing services for partners in the trade and development phase who want to market or want to market those products. For further information go to www. recrocdmo. com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate, among other things, to the company’s ability to manage costs and meet its financial goals. operate under increased leverage and associated credit arrangements; Pay off its debts under the loan agreement and maintain relationships with CDMO trading partners and establish additional trading partnerships. The words « anticipate », « believe », « could », « estimate », « imminent », « expect », « intend », « may », « plan », « predict », « project », « will » and Similar terms and expressions may be used to identify forward-looking statements in this press release. Our business activities involve risks and uncertainties, many of which are beyond our control, and any or a combination of which could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that could cause actual company results to differ materially from those expressed or underlying results in these forward-looking statements include the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse effects on ordering patterns the customer or the realignment or disruption of inventory in raw materials or supply chain; Demand for the company’s services, which depends in part on customer research and development, as well as clinical plans and market success of their products; changing warehouse requirements and customer manufacturing schedules; Customer and prospect decisions to advance the company’s manufacturing services; the average profitability or mix of products that the company makes; the company’s ability to improve existing or new services in a timely manner; Fluctuations in the costs, availability and suitability of the components of the products manufactured by the company, including active pharmaceutical ingredients, excipients, purchased components and raw materials, or of the company’s customers, which are exposed to increasing or new competition. These forward-looking statements should be viewed in conjunction with the risks and uncertainties that may affect our business and future results, as well as the risks and uncertainties discussed in our filings with the Securities and Exchange Commission at www. sec. government. These forward-looking statements are based on information currently available to us and we assume no obligation to update forward-looking statements unless required by law. Contacts Investor Relations Contact: Argot Partner Sam Martin / Claudia Styslinger (212) 600-1902 sam @ argotpartners. com Claudia @ argotpartners. com Recro Ryan D. . Lake (484) 395-2436 rlake @ recropharma. com Media contact: Argot Partners David Rosen (212) 600-1902 David. rosen @ argotpartners. com

From vaginal warts to masturbation, taboo-breaking Singaporean podcaster Nicole Lim deals with topics that, while squirming, have found a following in socially conservative Asian societies.

The famous Iditarod Trail Sled Dog Race through Alaska won’t run to Nome in 2021. This is a drastic change needed to protect the mushers from the COVID-19 pandemic and reduce its spread in rural Alaska, the race directors said Friday. Instead, the 2021 Iditarod Circuit leads racers and dogs halfway – the abandoned gold mining town of Iditarod, after which the trail is named. « After careful consideration, the board of directors has determined that the highest safety standards for canine and human athletes, volunteers and communities can be maintained. We look forward to the unique environment and challenges of this year’s race, « said Mike Mills, President of the Iditarod Board of Directors, in a statement.

Ferrari team boss Mattia Binotto says they « can’t accept » another year as bad as 2020 when the Italian F1 giant finished sixth, their worst season since 1980.

Residents of Western Australia’s Kimberley and parts of the Northern Territory have been told to prepare for widespread flooding.

According to health officials, Hong Kong authorities are looking for a COVID-19 positive patient who fled one of the city’s largest hospitals while on treatment. The 63-year-old man identified as patient 7379 was born on Jan.. Admitted to the isolation ward at Queen Elizabeth Hospital on December 23 after it was confirmed he had COVID-19. However, the man escaped from the infirmary by stairs on Friday and could not be retaken.

MONTREAL, Dec. . 18, 2020 (GLOBE NEWSWIRE) – Relevium Technologies Inc. . (TSX. V: « RLV », OTC: « RLLVF » and Frankfurt: « 6BX ») (the « Company » or « Relevium ») announce an update of its ongoing disclosure requirements and its previously disclosed Management Cease Trade Order (« MCTO »). , announced on Jan.. October 2020, in relation to the audited annual financial statements for the 30. The financial year ending June 2020, the interim financial statements for the first financial quarter for the three months ending 30. September 2020 and the corresponding management discussion and analysis for both submissions (together the « required financial filings ») that are not submitted by the required registration deadline on 28. October 2020 for the annual financial statements and on 30. November 2020 for the interim financial statements (the « Registration Deadlines »). The company has received further extensions of the registration deadlines for the necessary financial filings, which will be submitted at the earliest possible date and no later than December 15. January 2021 must be submitted. Because of this, management will keep the Trade Order Order or MCTO in effect until the required financial declarations have been submitted and require that the required financial declarations be submitted. Until the required financial reports are submitted, the company will publish standard status reports every two weeks in accordance with national guidelines 12-203 – Management Cease Trade Orders. The Company intends to meet the requirements of the Alternative Information Policy during the period in which the filing requirements are not met. The company confirms that, as of the date of this press release, there are no material business developments or other material information relating to its affairs that have not been generally disclosed. Aurelio Useche, CEO of Relevium stated, “The delays in filing the required financial information were due to two important facts. First, the company kept new examiners, RSM Canada LLP, which usually adds the added burden of a learning curve. The second reason was the impact of the COVID-19 pandemic on file creation, new information, and review ratings.  » Mr. Useche continued, “We are continuing to work diligently with our new auditors to complete both periods as quickly as possible. About Relevium TechnologiesRelevium is a publicly traded company active in the health and wellness industry, primarily focused on online sales. The company’s primary business is the identification, evaluation, acquisition, and operation of brands and companies in the health and wellness markets. The company recently entered the PSA business through acquisitions and partnerships as part of its strategy. It is a holistic approach that encompasses a wide range of health and wellness consumer products. Relevium operates through two wholly-owned subsidiaries: BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers, including Walmart. com and amazon. com. Biocannabix Health Corporation (BCX), headquartered in Montreal, Quebec, is a biopharmaceutical nutraceutical focused on the supply of pediatric endomedical nutraceuticals for cannabinoid therapy. Neither the TSX Venture Exchange nor its regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Cautionary Statement Regarding Forward-Looking Statements This press release contains certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and US securities laws. All statements in this press release, other than statements of historical fact, including statements about future estimates, plans, goals, assumptions or expectations regarding future performance, are forward-looking statements and contain forward-looking information. In general, forward-looking statements and information can be identified by the use of forward-looking terminology such as « intended » or « anticipated » or variations of such words and phrases or statements that « may » particular actions, events or results. « could », « should » or « would » occur. Forward-looking statements are based on certain significant assumptions and analyzes made by the company and on the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results, level of activity, performance, or performance of the company to differ materially from those expressed or implied in these forward-looking information. While management has attempted to identify important factors that could cause actual results to differ materially from those contained in any forward-looking statements or information, there may be other factors that could cause results not to be as expected , estimated, or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements and information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The company undertakes no obligation to update any forward-looking statements, forward-looking information, or financial prospects expressly incorporated herein by reference, except in accordance with applicable securities laws. We strive to rely on the applicable safe haven. On behalf of the Board of Directors, RELEVIUM TECHNOLOGIES INC. Aurelio Useche President and CEO Further information on this press release: Tel: 1. 888. 528. 8687 RELEVIUM TECHNOLOGIES INC Email: Investors @ releviumcorp. com website: www. relevant technologies. com Like us on Facebook Follow us on Twitter Follow us on LinkedIn

Ray Dalio, Greenwich, Bridgewater Associates, Barbara Dalio, Connecticut